HHS’s New Cannabis Proposal: What Rescheduling Means for the Industry
On August 29th, 2023, the US Department of Health and Human Services (HHS) marked a pivotal turn in the war on drugs transition of marijuana
Menu
On August 29th, 2023, the US Department of Health and Human Services (HHS) marked a pivotal turn in the war on drugs transition of marijuana
The U.S. cannabis and hemp industry currently lacks comprehensive product characterization, primarily due to limited state testing regulations in this area and a lack of
In this episode, we delved into lab testing issues in the cannabis industry, including lab shopping and THC inflation. We highlighted the need for a
The GMP Collective is a proud sponsor of the 2022 State of the States Report
published by the Americans for Safe Access (ASA). With over
Some of The GMP Collective’s experts including former FDA officials and senior quality engineers dive into the biggest cannabis industry news highlights of 2022 and
We all make mistakes. Small ones. Big ones. Some have immediate implications (you forget to look both ways and pull out of an intersection only
On August 29th, 2023, the US Department of Health and Human Services (HHS) marked a pivotal turn in the war on drugs transition of marijuana from Schedule I to Schedule III.
The U.S. cannabis and hemp industry currently lacks comprehensive product characterization, primarily due to limited state testing regulations in this area and a lack of widespread implementation of current Good Manufacturing Practices (cGMP). While most states focus on testing a few active molecules, namely Δ9-THC, Δ9-THCA, CBD, and CBD-A, full identification of product components is generally not required.
In this episode, we delved into lab testing issues in the cannabis industry, including lab shopping and THC inflation. We highlighted the need for a new perspective on flower potency testing and the importance of representative sampling. We also discussed the misconceptions about THC content and quality, and the complexities of CRM shopping, measurement uncertainty, and shelf stability.
The GMP Collective is a proud sponsor of the 2022 State of the States Report
published by the Americans for Safe Access (ASA). With over 150,000 active
supporters, ASA is the country’s largest member-based medical cannabis advocacy
group. Since 2014, the organization has published this comprehensive report that
grades the laws and regulations of U.S. states, D.C. and the four U.S. territories. If you
look at the reports over the years, it provides a snapshot of medical cannabis access
and regulatory progress. As time passes, ASA adapts the report with the times, adding
valuable sections, such as how states handled the COVID-19 response and starting to
give penalties for rules that limit patient access (Kentucky, New Mexico, and North
Carolina having the most penalties in this most recent report). ASA also updated the
rubric to prioritize the needs of patients today.
Some of The GMP Collective’s experts including former FDA officials and senior quality engineers dive into the biggest cannabis industry news highlights of 2022 and offer guidance and tools to position businesses for success in 2023.
We all make mistakes. Small ones. Big ones. Some have immediate implications (you forget to look both ways and pull out of an intersection only to end up in a car accident), while some implications aren’t realized until weeks or months later (a hinge or nut is not tightened to the right specification and comes loose over time before falling off). When it’s in your home, the impact may be minor and of short duration, but when it happens on a manufacturing line, the impacts can be significant. But all too often, these mistakes go unnoticed and undetected. How can you fix a problem if you don’t know what caused it in the first place?